img-3642-12bto2.jpg

First Endoscopic Minimally Invasive Spinal Procedure at Reston Hospital Center is Performed by Surgeons at Virginia Spine Institute

Posted On October 10, 2018 By OrthoSpineNews In Spine, Top Stories /  

RESTON, Va., Oct. 10, 2018 (GLOBE NEWSWIRE) — Dr. Colin Haines, assisted by Dr. Christopher Good, Spine Surgeons at Virginia Spine Institute, is the first physician to perform endoscopic spine surgery at Reston Hospital Center. Through a micro incision (less than 1cm), Dr. Haines and Dr. Good utilized the magnification of an HD-endoscope to perform a microdiscectomy. This surgical method allowed safer and more efficient removal of a disc herniation.

Minimally invasive procedures are now commonplace in spinal surgery, but endoscopic spine surgery utilizes ultra-minimally invasive technology that enhances traditional surgical technique. The advantage of a smaller incision (less than 1cm) and the introduction of a high-resolution camera minimizes tissue disruption and reduces post-operative pain for the patient. Typically performed as an outpatient procedure, patients undergo less anesthesia and experience improved recovery times.

A wide-reaching innovation, endoscopic spine surgery has promise to transform the lives of patients with degenerative disc disease, disc herniations, and spinal stenosis. This milestone is an essential breakthrough for future spinal procedures as the specialists at Virginia Spine Institute work to advance endoscopic technology for spinal fusions and spinal decompressions.

“Endoscopic spine surgery has unleashed new potential for faster, safer, and more effective surgical recoveries,” says Dr. Colin Haines, Spine Surgeon and Director of Research at Virginia Spine Institute. “I’m proud to dramatically improve the lives of patients suffering from back pain by pioneering treatment solutions like this that get them back to their active lifestyles faster.”

Dr. Colin Haines is an expert in minimally invasive surgical techniques that improve patient safety and reduce recovery time. These techniques include ultrasonic spine surgery, endoscopic spine surgery, and robot-guided spine surgery.

Dr. Christopher Good, Spine Surgeon and President of Virginia Spine Institute, specializes in the treatment of complex spinal conditions and is considered a world expert in the field of robotic spine surgery.

About Virginia Spine Institute: Virginia Spine Institute is an award-winning specialty medical practice in the Washington, DC metro area solely dedicated to spinal health care. For over 25 years they have improved the lives of over 85,000 patients suffering from back or neck pain conditions. This comprehensive spine center provides convenience of specialty care with the top experts from multiple specialties of spinal health care under one roof. Custom treatment options include non operative care, pain management, physical therapy, and when necessary surgical intervention, including minimally invasive, laser and robot-guided procedures. For more information about Virginia Spine Institute visit SpineMD.com.

Photo accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/71cbbbb0-a542-4be7-9ca8-c8047319cddf

http://www.globenewswire.com/NewsRoom/AttachmentNg/b8e761d3-ef29-4ea3-acb7-c71cdc88752b

Contact: Communications Director
Virginia Spine Institute
Tel: 703.709.1114 x 180
Email: 
SpineMD.com
Read More
1d2c76e445c828347fdd9adb97f29181-1-1-1.jpg

Implanet Reports 2018 Nine-Month Revenue

Posted On October 9, 2018 By OrthoSpineNews In Financial /  

October 09, 2018

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

Implanet (Paris:ALIMP) (OTCQX:IMPZY) (Euronext Growth: ALIMP, FR0010458729, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral and knee surgery implants, is today announcing its revenue for the third quarter and for the nine-month period ended September 30, 2018.

Implanet is holding a conference call at 9:30am this morning.
To join the call, please dial in on +33 (0)1 70 71 01 59 followed by the participant PIN code: 38620165#.

Ludovic Lastennet, Implanet’s Chief Executive Officer, commented: “Jazz® revenue increased 10% in France and 8% at constant exchange rates in the United States. Our strategy of building closer relationships with surgeons is paying off as the number of repeat surgeries has improved in key hospitals, including in the United States. This direct sales model has been up and running since early September in the United Kingdom, with Implanet UK and Jazz® now listed by the NHS. In Germany, Implanet GmbH subsidiary has been created and a sales director hired. This strategic realignment enables us to remain confident in our prospects for the coming months. The Jazz® activity did not offset the scheduled shutdown of the Arthroscopy business, impacting our total revenue by a decrease of 13% in the third quarter and by 10% at constant exchange rates over the last nine months.”

Revenue (in thousands of euros – IFRS*) 2018 2017 Change

Change at constant
exchange rates
First-quarter revenue 1,867 2,048 -9% -6%
Second-quarter revenue 1,765 2,071 -15% -12%
Spine (Jazz) 1,056 1,104 -4% -4%
Knee + Arthroscopy 491 671 -27% -27%
Third-quarter revenue 1,548 1,774 -13% -13%
Spine (Jazz) 3,254 3,506 -7% -4%
Knee + Arthroscopy 1,926 2,387 -19% -19%
Nine-month revenue 5,179 5,894 -12% -10%

*Unaudited data

Implanet recorded a fall of 12% in its total revenue over the nine-month period ended September 30, 2018. to €5.2 million (down 10% at constant exchange rates). The sales reorganization of the spine activities in Europe and the scheduled halt of the Arthroscopy business were the key factors.

Jazz® sales were stable to €1.1 million in the third quarter of 2018 and were down 7% over the first nine months of the year to €3.2 million (down 4% at constant exchange rates). They contributed 63% of total revenue, up from 59% in the same period of 2017.

Over the first nine months of the year, Implanet sold 6,579 units (vs. 6,296 in 2017).

Vibrant growth in Jazz® sales was evident over the first nine months of the financial year in France where they rose 10% to €1.2 million. In the United States, Jazz® sales grew to €1.6 million, up 8% at constant exchange rates.

As previously announced, Implanet intends to replicate the direct sales model, based on close surgeon relationships, which has proven its worth in France and the United States in order to accelerate the commercialization of Jazz® in the principal European markets.

Sales of the proprietary Madison product (knee prosthesis) were stable in France over the first nine months of the year and rose 11% during the third quarter. In the Rest of the World, the scheduled shutdown of the Arthroscopy business was the key factor behind the top-line contraction.

Implanet will be attending the following scientific conferences during Q4 2018:

SOFCOT in Paris from November 12 to November 15, 2018, stand F07
BSS (British Scoliosis Society) in Belfast from November 29 to November 30, 2018, stand 9
DWG in Wiesbaden (Germany) from December 6 to December 8, 2018, stand 102

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 46 staff and recorded 2017 sales of €7.8 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the BEOCABSA, OCA, BSA and the number of shares outstanding, is available on its website: http://www.implanet-invest.com/suivi-des-actions-80

Disclaimer

This press release contains forward-looking statements concerning Implanet and its activities. Such forward looking statements are based on assumptions that Implanet considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Implanet registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on April 16, 2018 under number D.18-0337 and available on the Company’s website (www.implanet-invest.com), and to the development of economic situation, financial markets, and the markets in which Implanet operates. The forward-looking statements contained in this release are also subject to risks unknown to Implanet or that Implanet does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Implanet that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for Implanet shares in any country.

1 NHS: National Health Service

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel. : +33 (0)5 57 99 55 55
investors@implanet.com
or
NewCap
Investor Relations
Julie Coulot
Tel. : +33 (0)1 44 71 20 40
implanet@newcap.eu
or
NewCap
Media Relations
Nicolas Merigeau
Tel. : +33 (0)1 44 71 94 98
implanet@newcap.eu
or
AlphaBronze
US-Investor Relations
Pascal Nigen
Tel.: +1 917 385 21 60
implanet@alphabronze.net

Read More
564_main-12bto.jpg

NuVasive Announces Strategic Partnership With Biedermann Technologies To Access Intellectual Property And Co-Develop State-of-the-Art Complex Spine Solution

Posted On October 9, 2018 By OrthoSpineNews In Spine /  

SAN DIEGO and DONAUESCHINGEN, GERMANY, Oct. 9, 2018 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it has entered into a strategic partnership with Biedermann Technologies GmbH & Co. KG, a company that holds a broad and extensive patent and technology portfolio in the fields of spinal and extremity surgery, based in Donaueschingen, Germany.

Biedermann Technologies is well regarded for its world-class design expertise within many medical device industries and holds one of the most comprehensive and innovative patent portfolios in the field of spinal surgery. Within the terms of the license and services agreement, Biedermann Technologies has granted NuVasive licenses to intellectual property relating to its spinal technology portfolio.

Specifically, certain Biedermann Technologies’ proprietary screw innovations will be integrated into the NuVasive RELINE® portfolio, offering surgeons a superior solution to treat complex spinal pathologies in both the adult and pediatric populations for open, as well as minimally invasive surgery, with customized screw placement and ability to facilitate various corrective maneuvers based on the clinical needs of the patient. NuVasive’s RELINE system is the only technology on the market to offer a single tulip that accepts three posterior fixation rods of different diameters and is integrated into its proprietary Integrated Global Alignment (iGA®) platform designed to achieve global alignment across spinal procedures. This combination of Biedermann Technologies’ propriety screw technology and NuVasive’s RELINE system is expected to be commercially available to surgeons in the first half of 2019.

Biedermann Technologies will also provide services to NuVasive in connection with the development of its next-generation RELINE complex spine system to support three foundational clinical pillars: surgical efficiency, operative reliability and procedural versatility.

“Partnering with Biedermann Technologies —a highly innovative medical device design powerhouse—coupled with NuVasive’s best-in-class engineering teams and innovation prowess—will accelerate the development and time-to-market to put the most advanced posterior fixation solutions in the hands of our surgeon partners,” said Matt Link, executive vice president, Strategy, Technology and Corporate Development of NuVasive. “This partnership will help create better, more reproducible clinical outcomes in some of the hardest to treat spine pathologies, and further demonstrates our commitment to R&D investments to create the future of leading complex spinal innovation.”

“Significant challenges demand smart collaborations,” said Lutz Biedermann, founder and president of Biedermann Technologies. “And reconstructive spine surgery of complex deformities and instabilities of all age groups is still such a significant clinical challenge. With this in mind, I welcome the opportunity to work with NuVasive’s very talented and skilled organization to offer clinically meaningful solutions to the global spine community.”

NuVasive will showcase the upcoming RELINE system featuring Biedermann Technologies’ innovations at the Scoliosis Research Society Annual Meeting held October 10-13, 2018 in Bologna, Italy.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

About Biedermann Technologies
Biedermann Technologies GmbH & Co. KG is a privately held company based in the South of Germany and is the owner and guardian of a substantial patent and technology portfolio for specialized orthopedic markets. For the last 25 years, Biedermann Technologies has successfully licensed numerous patents and related technologies to several key players in the orthopedic and neurosurgical field.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Read More
medovex-7x4.jpg

Medovex Corporation Names William E. Horne Chief Executive Officer and Chairman of the Board

Posted On October 9, 2018 By OrthoSpineNews In Spine, Top Stories /  

ATLANTA, Oct. 09, 2018 (GLOBE NEWSWIRE) — Medovex Corp. (OTCQB: MDVX), (“Medovex” or the “Company”), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to chronic back pain, a non-addictive, non-opioid drug alternative capable of restoring a patient to a more normal and active lifestyle, today announced that it has named William “Bill” Horne as the Company’s Chief Executive Officer and Chairman of its Board of Directors.

Bill Horne is a founder and former Chief Executive Officer and Chairman of the Board of Laser Spine Institute. From 2005 to 2015, Horne served as the company’s CEO, expanding the homegrown organization from one facility with nine employees, to seven state-of-the-art surgery centers with more than 1,000 employees across six states, while driving annual revenues as high as $288M during his tenure. In his role as Chairman of the Board, he led the strategic direction of the company, which has made it possible for more than 75,000 patients to take back their lives from chronic pain with its minimally invasive spine procedures.

Horne’s desire to found and cultivate Laser Spine Institute was derived from an extremely personal place, his own experience. Horne himself suffered from chronic back pain before having his own minimally invasive spine surgery. That experience drove him to found Laser Spine Institute. He believed in creating a company that offered relief from chronic neck and back pain coupled with a superior patient experience.

Bill Horne stated, “I’m excited to join Medovex at what I view as an opportunistic time. I’ve long felt that the Company’s DenerveX System represented a highly disruptive longer-term solution to chronic lower back pain associated with the Facet Joint, a sizeable market opportunity that continues to see large growth. Importantly, it’s a market I’m intimately familiar with, having been one of the founders of Laser Spine Institute.”

Horne continued, “My initial goal as CEO of Medovex will be to immediately pursue both synergistic and accretive opportunities that have the potential of achieving near-term greater scale, while best positioning us to leverage that increased scale with the intent of unlocking and maximizing the true value of the DenerveX System. I look forward to hitting the ground running and executing our plan, solely focused on building measurable shareholder value.”

Jarrett Gorlin, Medovex’s outgoing Chief Executive Officer, stated, “Bill’s proven track record as a leader in multiple industries including healthcare speaks for itself. To say we are excited to have attracted such a highly accomplished CEO and Chairman would be an understatement. Our entire management team and board of directors is confident in Bill’s vision, experience and track record of building enterprise value. Together we believe the decision to name him our new CEO and Chairman is in the best of interest of our shareholders.”

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company’s first pipeline product, the DenerveX System, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com.

Safe Harbor Statement

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Medovex believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the company’s filings with the U.S. Securities and Exchange Commission. Thus, actual results could be materially different. Medovex expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT INFORMATION

  • Medovex Corp.
    Jason Assad
    678-570-6791
    Jassad@medovex.com
Read More
Ossur_Logo_2014-12bto.jpg

Ossur Hf : Share buyback program completed

Posted On October 8, 2018 By OrthoSpineNews In Financial /  

Reykjavík, 8 October 2018

On 6 March 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 16/2018.

The purpose of the share buyback program was to reduce the Company’s share capital and adjust the capital structure by distributing capital to shareholders in line with the Company’s Capital Structure and Dividend Policy. The program would end no later than 28 February 2019. The Company could purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital. The total consideration for shares purchased under the program could not exceed USD 10 million.

Össur acquired 2,130,549 shares under the program at the average price of DKK 30.05. The total consideration amounted to USD 10 million (approx. DKK 65 million) and thus the program has been completed. Össur currently holds 6,143,780 own shares, corresponding to 1.4% of the Company’s total share capital.

The share buyback program was carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (“MAR”), and the Commission delegated regulation No. 2016/1052.

Contact persons:

Jón Sigurðsson, President & CEO     Tel: +354 515 1300

Sveinn Sölvason, CFO     Tel: +354 515 1300

Össur press releases by e-mail: If you wish to receive Össur press releases by e-mail please register at the following web-site: http://www.ossur.com/investormailings

About Össur Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopedics that help people live a life without limitations. Its business is focused on improving people’s mobility through the delivery of innovative technologies within the fields of braces, supports and prosthetic limbs. A recognized “Technology Pioneer”, Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur’s educational programs and business solutions.  Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com

Forward-Looking Statement This press release includes “forward-looking statements” which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Read More
TRANS1-12bto2.png

TranS1® Announces NICE Guidance for Approval of AxiaLIF® in the UK’s National Health System (NHS)

Posted On October 8, 2018 By OrthoSpineNews In Spine /  

WILMINGTON, N.C., Sept. 18, 2018 /PRNewswire/ — TranS1®, an innovator in spine technology development that pioneered the anterior retroperitoneal presacral approach utilizing the AxiaLIF® System, announced today that the UK’s National Institute for Health and Care Excellence (NICE) published its Interventional Procedure Guidance recommendation for  transaxial interbody lumbosacral fusion for severe chronic low back pain.1 The guidance recommended that the procedure be available to properly indicated patients in the UK’s National Health System (NHS).  This recommendation places TranS1’s presacral approach and AxiaLIF System in the same ‘standard arrangements’ category as other widely used MIS technologies such as Lateral Lumbar Interbody Fusion (LLIF) and MIS SI Joint Fusion.

NICE develops guidance and quality standards in health and social care and is a worldwide leader in technology evaluations.  NICE’s role is to improve outcomes for people using the NHS and other public health services2.

TranS1’s AxiaLIF (Axial Lumbar Interbody Fusion) System is a minimally invasive spinal fusion option designed to create a safe anterior retroperitoneal presacral pathway to the L5-S1 segment without the destabilizing muscle and ligament damage associated with traditional anterior or posterior lumbosacral fusion techniques.  Citing potential benefits of the presacral approach including “faster recovery and less postoperative morbidity compared to conventional spinal fusion surgery,” NICE based its guidance recommendation on a comprehensive literature search and detailed review process1.

“The ‘standard arrangement’ recommendation by NICE only further solidifies that the AxiaLIF technology is not investigational or experimental and is a viable treatment option for surgeons and their patients not only in the UK but worldwide,” said John D. Miller, President & CEO of TranS1.  “Our AxiaLIF System is an important foundational element of our business that we plan to leverage as we execute on our reimbursement strategy.”

About TranS1®
Recently relocated back to its roots in Wilmington, NC – TranS1 is a pioneer in spine technology innovation and is focused on Building Better Pathways™ to the spine.  Since its inception, TranS1 has designed, developed, and commercialized transformational approaches to the spine used by thousands of surgeons to minimize the damage associated with traditional surgical approaches.  TranS1 believes that the process of Building Better Pathways™ to the spine starts with solving true unmet clinical needs and ends with creating a value-based solution for surgeons, patients, and the healthcare system.

With more than 18,000 AxiaLIF procedures performed in the last 12 years, the ‘arthrodesis, presacral interbody technique’ is recognized by the American Medical Association (AMA) as a Category 1 CPT code 22586, non-experimental procedure. The AxiaLIF System is the only presacral approach spinal fusion approved by the US Food and Drug Administration (FDA) with over 90 peer reviewed publications citing its safety and efficacy.  For more information, please visit www.TranS1.com or email John Miller at contact@TranS1.com. Please connect with us on LinkedIn, Twitter, & Facebook.

  1. NICE Interventional Procedures Guidance [IPG620]. July 2018. https://www.nice.org.uk/guidance/ipg620/chapter/1-Recommendations
  2. https://www.nice.org.uk/about/who-we-are/our-charter

SOURCE TranS1

Related Links

www.trans1.com

Read More
stryker-headquarters-1.jpg

Stryker’s Advanced Guidance Technologies announces partnerships with Synaptive Medical and Ziehm Imaging

Posted On October 8, 2018 By OrthoSpineNews In Spine /  

KALAMAZOO, Michigan, USA, Oct. 8, 2018 /PRNewswire/ — Stryker’s Advanced Guidance Technologies business (formerly known as Stryker’s Navigation business) announced today it has entered into strategic partnerships with Synaptive Medical and Ziehm Imaging, strengthening Stryker’s position as a leader in surgical guidance.

Through the partnership with Synaptive Medical, Stryker will offer the BrightMatter™ Plan software, which automatically generates high-fidelity, dynamic, whole-brain tractography.  Surgeons can easily review tracts and explore multiple surgical approaches to create powerful pre-operative plans—for every case.  Tractography can be used, without disrupting surgical workflow, to confirm the data is concordant with the intended approach and determine whether detailed surgical planning is required. Then, the surgical plans can be easily exported for navigation in the operating room.

BrightMatter Plan is the only tractography offering that is automated and whole-brain.  Other solutions on the market require a neuroradiologist or other tractography expert to generate tracts, which is both time consuming and a road block for surgeons.

“We are committed to providing our customers with a complete solution for surgical guidance,” said Lisa Kloes, General Manager of Stryker’s Advanced Guidance Technologies business. “The partnerships with Synaptive Medical and Ziehm Imaging are an important step in that direction.”

The Ziehm Vision RFD 3D C-arm, which Stryker will now offer as part of its agreement with Ziehm Imaging, offers the latest flat-panel technology for CT-like image quality, giving surgeons access to detail-rich imaging that provides the accuracy and efficiency required in demanding orthopaedic, trauma or spinal procedures, all with minimized dose and less time.

Over the last several years, Stryker’s Advanced Guidance Technologies’ product and service offerings have evolved beyond the traditional scope of navigation to also include Imaging, Augmented Reality and Planning Software. With the addition of BrightMatter Plan and Ziehm Vision RFD 3D C-arm to its portfolio, Stryker’s Advanced Guidance Technologies reinforces its commitment to providing customers with better and complete surgical guidance solutions.

To learn more about this expanded portfolio, please visit booth #1529 at The Congress of Neurological Surgeons (CNS).

About Stryker
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical, Surgical, Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.

Media contact
Jennifer Lentner 
jennifer.lentner@stryker.com

SOURCE Stryker

Related Links

http://www.stryker.com

Read More
72c124ba3045322e6c0468d5bad23357-12bto.png

Additive Orthopaedics Announces Receipt of NJ CoVest Fund Award

Posted On October 8, 2018 By OrthoSpineNews In Financial /  

LITTLE SILVER, N.J., Oct. 8, 2018 /PRNewswire/ — Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, today announced it has been approved for the NJ CoVest Fund through the New Jersey Economic Development Authority (EDA). The Fund is designed to help emerging technology companies bridge the funding gap between product development and commercialization.

According to Greg Kowalczyk, President of Additive Orthopaedics, “This is a tremendous honor and opportunity that we are privileged to accept from the State of New Jersey. We are now able to add additional corporate resources to provide even more limb salvage solutions to patients that were previously unavailable.”

EDA Chief Executive Officer Tim Sullivan noted the important role the Fund plays in fostering innovation across the Garden State and furthering the EDA’s ability to support businesses throughout their growth lifecycle.

“Ensuring that pioneering companies like Additive Orthopaedics have access to critical capital between product development and commercialization is a pivotal step in re-establishing New Jersey as a leader in innovation,” Sullivan said. “We are especially pleased that Additive Orthopaedics plans to use the funding from its NJ CoVest loan to expand its workforce.”

Additive Orthopaedics has already seen a growing market need in 2018 for 3D printed orthopaedic complex reconstruction, limb salvage, and revision implants, and will continue to address patient conditions where there are no commercially available devices on the market.

Recent Updates from Additive Orthopaedics, LLC.
Additive Orthopaedics recently became the leading sponsor in the American Society of 3D Printing. Launched in 2017, the mission of the society is to provide an educational forum for surgeons involved in clinical treatments leveraging 3D printing and to support patients in need.

About Additive Orthopaedics, LLC.
Additive Orthopaedics is an early stage orthopaedic company focused on the integration of advanced manufacturing and biologics to improve patient outcomes.

About the NJ CoVest Fund
The NJ CoVest Fund provides funding to New Jersey technology and life sciences companies to further commercialize their technology and scale revenues. Investments made through the NJ CoVest Fund align with the EDA’s ongoing strategy of supporting New Jersey’s entrepreneurial ecosystem.

Contact:
Greg Kowalczyk
732.882.6633
greg@additiveorthopaedics.com

SOURCE Additive Orthopaedics, LLC.

Related Links

http://www.additiveorthopaedics.com

Read More
18920318-190802371445693-995558016287136828-n.jpg

Corin signs binding agreement for the acquisition of Global Orthopaedic Technology

Posted On October 5, 2018 By OrthoSpineNews In Financial /  

Cirencester, UK Corin, backed by the Permira Funds is pleased to announce the signing of a binding agreement for the acqusition of Global Orthopaedic Technology Pty Ltd (“GOT”), the largest Australian-based orthopaedic implant designer and manufacturer.

The acquisition will strengthen Corin’s position as a global leader in the hip and knee joint replacement market and is a testament to Corin’s accelerated global expansion and focus on innovation. Corin’s R&D Hub in Australia is a key pillar of its global innovation capabilities and differentiated product offering. The combination with GOT provides significant scale to Corin’s operations in Australia – one of the world’s most attractive orthopaedics markets, as well as additional R&D expertise.

Global Orthopaedics Technology formed 19 years ago, offers an extensive range of orthopaedic implants including knee and hip products with enabling robotics and navigation technologies. The company has a significant Australian footprint and an export business in the USA.

Stefano Alfonsi, Chief Executive Officer of Corin, commented, “This agreement will further strengthen our presence in the sophisticated and competitive Australian market. The combination of Corin and GOT capabilities creates a leading player in Australia with stronger ability to fulfill the needs of hip and knee surgeons. I look forward to welcoming the talented GOT team into the Corin global family.”

Andrew Fox-Smith, Chief Executive Officer of GOT said, “Our acquisition by Corin represents a fantastic next step for both our people and our customers. Corin has an excellent track record in the total joint replacement market and their dynamic and innovative culture is a natural fit to how we have been operating over the last 4 years. We’re very excited about what the combined business can achieve, not only here in Australia but also via faster expansion internationally of GOT’s Australian developed product portfolio.”

Silvia Oteri, Partner with Permira, commented, “The Permira funds backed Corin and its outstanding management team as it is a strong and ambitious leader in its market with a clear vision to revolutionise orthopaedics. The GOT acquisition represents an important step forward in building a leading and innovative successful platform in the space.”

Media Enquiries
For Corin
Elvio Gramignano, Global Strategic Marketing Director
+44 (0) 1285 884 725
+44 (0) 7769 883 675
elvio.gramignano@coringroup.com

Vaughan Bonny Managing Director, Australia and New Zealand
+61 (0)2 94977400
Mobile: +61 (0)437 777 121
vaughan.bonny@coringroup.com

For Permira 
James Olley (Montfort Communications)
+44 203 770 7909
jolley@montfort.london

Notes to Editors

About Corin 

Headquartered in Cirencester, UK, Corin is an international orthopaedic company with a direct presence in a majority of the world’s orthopaedic markets and a track record of strong double-digit growth. Corin’s vision is to revolutionise orthopaedics by gaining, understanding and sharing insight at every stage of the arthroplasty experience. The unique combination of shared knowledge and clinically-proven implants delivers better outcomes and maximises healthcare value for patients, surgeons and healthcare providers.

About Global Orthopaedic Technology 
GOT was formed 19 years ago and is the largest Australian-owned orthopaedic implant designer and manufacturer. It has a significant footprint throughout Australia and an export business in the USA, with plans to expand to Asia and Europe. It offers an extensive range of orthopaedic implants including knee and hip products, as well as providing enabling technologies such as robotics and navigation methodologies.

About Permira 
Permira is a global investment firm. Founded in 1985, the firm advises private equity funds with a total committed capital of over €33bn and makes long-term majority and strategic minority investments in companies with the objective of transforming their performance and driving sustainable growth. The Permira funds have made over 250 private equity investments in five key sectors: Consumer, Technology, Industrials, Healthcare and Financial Services.

Permira employs over 200 people in 14 offices across Europe, North America and Asia. For more information please visit www.permira.com.

Posted 2 days ago by Harriet Allen

Read More
64083_1_33485-1024x495-12bto.jpg

3D-Printed Implants Successful in Foot and Ankle Surgery

Posted On October 5, 2018 By OrthoSpineNews In Extremities /  

ROSEMONT, Illinois, Oct. 5, 2018 /PRNewswire-HISPANIC PR WIRE/ — According to a new study published in Foot & Ankle International (FAI), advancements in three-dimensional (3D) printing have allowed foot and ankle orthopaedic surgeons to use custom-made implants for difficult foot and ankle cases. The implants offer a new approach to treat complex lower extremity pain and deformities.

Researchers at Duke University Department of Orthopaedic Surgery studied 15 patients who received custom 3D-printed titanium implants between 2014 and 2016 to treat poor bone quality, bone loss, and deformity. In each case, the implants were initially developed by obtaining a computed tomography (CT) scan of the patient and uploading the data to a software program that allowed 3D manipulation of the bones and joints. From there, the senior surgeon and company engineers designed and approved the implant. The benefits of 3D-printed implants include unlimited shapes, increased options in size, and less morbidity or complications.

“This is the first case series looking at the use of 3D-printed implants in foot and ankle surgery,” said Samuel B. Adams, MD, director of foot and ankle research at Duke University Medical Center and senior author of the study. “This short-term study is also the first to demonstrate improvement in patient-reported outcomes with the use of 3D-printed implants. The injuries of many of the patients treated in this study would have required an amputation without this technology.”

CT scans showed that the custom 3D-printed titanium implants were successful in 13 of 15 of the patients who took part in the study. The patients with successful outcomes reported significant improvement in pain and stated they would undergo the same procedure again to save their foot or ankle.

The authors of the study suggest that 3D printing could revolutionize medical care, specifically in modeling for medical education and creating custom artificial body parts. The study notes that longer-term follow-up is needed to understand the longevity and potential complications of these 3D-printed implants.

“The future of 3D printing is very bright. Surgeons who may have been skeptical about using this technology can now use this data to make an informed decision about using it to improve patient care,” said Dr. Adams.

The study, “Use of Patient-Specific 3D-Printed Titanium Implants for Complex Foot and Ankle Limb Salvage, Deformity Correction, and Arthrodesis Procedures,” appears in the August 2018 issue of Foot & Ankle International, the official journal of the American Orthopaedic Foot & Ankle Society (AOFAS). FAI is published by SAGE Journals. Author conflicts of interest and funding information are provided within the study.

About Foot and Ankle Orthopaedic Surgeons 
Foot and ankle orthopaedic surgeons are medical doctors (MD and DO) who specialize in the diagnosis and treatment of musculoskeletal disorders and injuries of the foot and ankle. Their education and training consists of four years of medical school, five years of postgraduate residency, and a fellowship year of specialized surgical training. These specialists care for patients of all ages, performing reconstructive surgery for deformities and arthritis, treating sports injuries, and managing foot and ankle trauma.

About the AOFAS 
The American Orthopaedic Foot & Ankle Society (AOFAS) mobilizes our dynamic community of foot and ankle orthopaedic surgeons to improve patient care through education, research, and advocacy. As the premier global organization for foot and ankle care, AOFAS delivers exceptional events and resources for continuous education, funds and promotes innovative research, and broadens patient understanding of foot and ankle conditions and treatments. By emphasizing collaboration and excellence, AOFAS inspires ever-increasing levels of professional performance leading to improved patient outcomes. For more information visit the American Orthopaedic Foot & Ankle Society online at aofas.org.

Logo – https://mma.prnewswire.com/media/328804/american_orthopaedic_foot___ankle_society.jpg

SOURCE American Orthopaedic Foot & Ankle Society

Related Links

http://www.aofas.org

Read More